Share

Quotes

We are very pleased with having initiated this confirmatory clinical study investigating the safety and efficacy of anakinra in people with Still’s disease. This is a disease affecting both young people and adults and is associated with a significant morbidity and with a large unmet medical need
Milan Zdravkovic, Senior Vice President, Chief Medical Officer and Head of Research & Development at Sobi.
Krassimir Mitchev, MD, PhD, Vice President and Medical Therapeutic Area Head of Haemophilia at Sobi
We are very encouraged by the results of this study as they reinforce the positive impact prophylactic treatment with Elocta/ELOCTATE has the potential to provide on joint health and patient outcomes
A strong business performance was shown across the portfolio in the third quarter, with the main contributors being Elocta and Alprolix. Elocta sales increased more than 600 per cent compared to the same period last year and Alprolix sales increased with approximately 500 per cent. This strong growth momentum encourages us to be confident around the prospects of our Haemophilia franchise.
Guido Oelkers, CEO
We are delighted that Norbert could join Sobi. Norbert is a true entrepreneur, and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our Specialty Care business
Guido Oelkers, President and CEO of Sobi
We are very happy to receive the approval by the FDA of the new dosing frequency for Orfadin. Orfadin is the first nitisinone product approved for once daily use in the US This is an important step towards reducing the treatment burden of people with HT-1 and it follows Sobi’s introduction of Orfadin 20mg capsules and Orfadin oral suspension
Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi.
New data will reinforce that Elocta and Alprolix treatment can maintain low ABRs, therefore helping improve the long-term quality-of-life for people with haemophilia A and B
Krassimir Mitchev, MD, PhD, Vice President and Medical Therapeutic Area Head of Haemophilia at Sobi
We are very pleased with the orphan drug designation from the FDA for SOBI003. MPS IIIA is a severe and debilitating disease, and this development program is an important part of our mission of being pioneers in rare diseases. We are currently in the late pre-clinical phase and expect to initiate the first clinical trial with SOBI003 in 2018
Milan Zdravkovic, Chief Medical Officer and Head of Research and Development at Sobi.
The availability of funding for Xiapex within NHS England is an important milestone for the Dupuytren’s community in the UK, as healthcare professionals can now offer people with contracture a non-invasive treatment option
Neil Dugdale, General Manager UK & RoI at Sobi
We are committed to improving the lives of people with Haemophilia B, and consider this an important step forward to reduce the treatment burden
Milan Zdravkovic, Senior Vice President, Chief Medical Officer and Head of Research & Development at Sobi
The approval of Elocta in Saudi Arabia is an important development for the haemophilia community in the Middle East and will enable physicians to offer their patients a wider range of treatment options
Ahmad Abu-Dahab, Regional Director Middle East, & Turkey
obi’s vision is to support that patients are diagnosed at birth, receive effective and sustainable therapy, and go on to live full and healthy lives no matter where in the world they live. This approval is another important step on this journey,
Bodil Jonason, Vice President Commercial Operations and Head of Global Brands at Sobi.
We took a major step in 2016 by launching Elocta and Alprolix, two first in class extended half-life Fc fusion clotting factors to people with haemophilia in Europe and in parts of the Middle East
Geoffrey McDonough
Sobi has a long-term commitment to improve the lives of people living with HT-1, and the modified storage recommendation is a further step in this journey
Bodil Jonason, Vice President Commercial Operations and Head of Global Brands at Sobi
The interim data from B-YOND confirm the safety profile of Alprolix, and show that adult, adolescent and paediatric subjects maintained low annual bleed rates with prophylactic dosing of Alprolix every 1-2 weeks
John Pasi, MD, PhD, principal investigator of the study, Professor of Haemostasis and Thrombosis at The Royal London Hospital, Barts and the London School of Medicine and Dentistry
“Sobi is committed to providing a consistent and reliable supply of Elocta across our territories and the recent EMA approval is another important step toward fulfilling that commitment
Philip Wood, Vice President and Commercial Therapeutic Area Head Haemophilia at Sobi
Through Fc fusion technology, Alprolix uses the body’s natural pathway to prolong the time the therapy remains in the body
Krassimir Mitchev, MD, PhD, vice president and medical therapeutic area head of haemophilia at Sobi
Sobi has a long-term commitment to improve the lives for people affected by hereditary tyrosinemia type 1, and the above modified dosing regimen is a further step in this journey
Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi.
A-SURE is an important study which aims to evaluate the effectiveness of Elocta in a real world-setting
Stefan Lethagen, Vice President Medical & Clinical Sciences, Haemophilia at Sobi
There is a persistent and significant unmet medical need for resolving pain in people affected by acute gout, and there is a strong scientific rationale for investigating the safety and efficacy of anakinra in this disease
Milan Zdravkovic, Senior Vice President, Head of Research & Development at Sobi
“Sobi has been committed to supporting the HT-1 community globally for more than two decades, and we were the first to develop this treatment and make it available in Canada through Health Canada’s Special Access Programme
Bob McClay
We are happy to build on our successful relationship with Horizon Pharma to support providing treatment to people living with UCDs
Alan Rafensperger
We believe that Sobi's current distribution of Ammonaps uniquely qualifies it to effectively provide Ravicti to people living with UCDs in European markets.”
Francoise de Craecker
The overall results indicate that there is a significant need to advance standard of care within haemophilia
Stefan Lethagen, Vice President Medical & Clinical Sciences, Haemophilia at Sobi.
MPS IIIA is a severe and debilitating disease with devastating consequences for patients. We hope that SOBI003 will provide these patients with a treatment where there is none today
Stephen James, Head of Research and Translational Sciences
Securing reimbursement for Alprolix across the UK, relatively soon after EU marketing authorisation approval is an important milestone toward making this new development in haemophilia B therapy available to people and families living with haemophilia B
Neil Dugdale, General Manager UK & Republic of Ireland
Milan brings an creative global translational and development profile which can build and expand upon our strong legacy of biologics innovation.”
Geoffrey McDonough, President and CEO at Sobi
This extensive post approval clinical experience with Elocta complements the clinical data generated by our pivotal clinical studies, and follows the findings of the long term ASPIRE extension study. We believe that this comprehensive clinical data and real world experience can provide support to clinicians and patients while making their treatment choices as Elocta becomes available in additional countries
Krassimir Mitchev
Pick a time period -
There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe